Page last updated: 2024-10-26

doxapram and Apnea

doxapram has been researched along with Apnea in 58 studies

Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.

Apnea: A transient absence of spontaneous respiration.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants."9.41Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023)
"Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants."9.22Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. ( Benard, M; Boutroy, MJ; Casper, C; Greze, E; Haddad, FE; Hamon, I; Hascoët, JM, 2016)
"Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator."9.11Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005)
"Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0."9.09Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999)
"A blinded, randomized, placebo-controlled trial was conducted to evaluate the effectiveness of theophylline and doxapram therapy in 31 infants with significant apnea of prematurity."9.06A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. ( Finer, NN; Peliowski, A, 1990)
"A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity."9.05Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. ( Alpan, G; Arad, I; Dgani, Y; Eyal, F; Glick, B; Peleg, O; Sagi, E, 1985)
"The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline."8.95Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017)
" The diagnosis of apnea of prematurity (AOP) is one of exclusion."8.82Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003)
" theophylline, aminophylline or caffeine) for the treatment of apnea in preterm infants."8.80Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000)
"Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants."8.80Current options in the management of apnea of prematurity. ( Bhatia, J, 2000)
"In preterm infants with recurrent apnea, how does treatment with doxapram compare with treatment with theophylline in leading to a clinically important reduction in apnea and use of mechanical ventilation, without clinically important side effects."8.80Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000)
"Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)."7.83Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016)
" There was a marked difference in the cumulative dosage and duration of doxapram therapy used for apnea of prematurity (total dose 2233 +/- 1927 mg vs 615 +/- 767 mg, P < ."7.71Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. ( Demianczuk, N; Etches, PC; Robertson, CM; Sreenan, C, 2001)
"An approximate 80% reduction in the frequency of apnea was found with only minimal side effects following low-dose doxapram."7.71Low-dose doxapram therapy for idiopathic apnea of prematurity. ( Fujimura, M; Itahashi, K; Kajiwara, M; Yamazaki, T, 2001)
"Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment."7.70[Treatment of apnea in prematurity]. ( Boutroy, MJ; Hascoët, JM, 1998)
"5 mg/kg/h) doxapram may help wean from positive airway pressure very low birthweight (less than or equal to 1250 g) infants with apnea unresponsive to aminophylline."7.68Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants. ( Brion, LP; Reinersman, G; Roth, P; Vega-Rich, C, 1991)
"The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea."7.68Doxapram for the initial treatment of idiopathic apnea of prematurity. ( Bairam, A; Faulon, M; Monin, P; Vert, P, 1992)
"We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects."7.68Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991)
"5 mg/kg/h theophylline) were administered in that order and in reverse order to patients with apnea of prematurity."7.68Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity. ( Coutts, RT; Finer, NN; Jamali, F; Malek, F; Peliowski, A, 1991)
"Eighteen infants with idiopathic apnea of prematurity refractory to therapeutic levels of aminophylline were treated with incremental doses of doxapram beginning at 0."7.67Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, G, 1987)
"Pharmacokinetics of doxapram were determined in 13 infants with idiopathic apnea of prematurity uncontrolled by aminophylline and caffeine."7.67Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ( Beaudry, MA; Bradley, JM; Gramlich, LM; LeGatt, D, 1988)
"Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2."7.67Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986)
" The final pharmacokinetic model was as follows: CL = BW / PMA × 0."6.80Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. ( Irie, T; Irikura, M; Ishitsuka, Y; Kamada, N; Kobaru, Y; Kochiyama, Y; Kondo, Y; Ogawa, Y; Ohno, H; Tomiyasu, M; Uriu, M; Yamazaki, T; Yukawa, E, 2015)
"To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants."5.41Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023)
" Other pharmacokinetic indices, although variable, did not exhibit binomial distribution."5.27Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, GA, 1988)
"Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants."5.22Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. ( Benard, M; Boutroy, MJ; Casper, C; Greze, E; Haddad, FE; Hamon, I; Hascoët, JM, 2016)
"Doxapram is used to treat apnea of prematurity when there is an insufficient response to methylxanthine treatment."5.11Effect of doxapram on cerebral blood flow velocity in preterm infants. ( Horsch, S; Roll, C, 2004)
"Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator."5.11Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005)
"Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0."5.09Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999)
"A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity."5.05Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. ( Alpan, G; Arad, I; Dgani, Y; Eyal, F; Glick, B; Peleg, O; Sagi, E, 1985)
"The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline."4.95Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017)
" The diagnosis of apnea of prematurity (AOP) is one of exclusion."4.82Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003)
"Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants."4.80Current options in the management of apnea of prematurity. ( Bhatia, J, 2000)
" theophylline, aminophylline or caffeine) for the treatment of apnea in preterm infants."4.80Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000)
"In preterm infants with recurrent apnea, how does treatment with doxapram compare with treatment with theophylline in leading to a clinically important reduction in apnea and use of mechanical ventilation, without clinically important side effects."4.80Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000)
"The cerebral metabolic and circulatory effects of the two main classes of respiratory stimulants used in the apnea of the newborn and premature infant, i."4.79Effects of respiratory stimulants on cerebral metabolism and blood flow. ( Nehlig, A, 1994)
"Apnea of prematurity can persist despite caffeine therapy in preterm infants."4.02The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Koch, BCP; Poets, CF; Reiss, IKM; Simons, SHP; Völler, S, 2021)
"Doxapram is a treatment option for severe apnea of prematurity (AOP)."3.91Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. ( de Jongh, FH; de Waal, CG; Hutten, GJ; Kraaijenga, JV; van Kaam, AH, 2019)
"Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)."3.83Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016)
"Methylxanthines and doxapram have been used to stimulate breathing and to prevent apnea in preterm infants."3.73[Determinants of doxapram utilization: a survey of practice in the French Neonatal and Intensive Care Units]. ( Bénard, M; Boutroy, MJ; Casper, C; Glorieux, I, 2005)
"Doxapram is a respiratory stimulant widely used for the treatment of idiopathic apnea of prematurity, although it has been demonstrated that it can induce a transient decrease of cerebral blood flow and that isolated mental delay in infants weighing <1,250 g is associated with the total dosage and duration of doxapram therapy."3.73Brain hemodynamic effects of doxapram in preterm infants. ( Bertini, G; Dani, C; Filippi, L; Pezzati, M; Pratesi, S; Rubaltelli, FF; Tronchin, M, 2006)
"An approximate 80% reduction in the frequency of apnea was found with only minimal side effects following low-dose doxapram."3.71Low-dose doxapram therapy for idiopathic apnea of prematurity. ( Fujimura, M; Itahashi, K; Kajiwara, M; Yamazaki, T, 2001)
" There was a marked difference in the cumulative dosage and duration of doxapram therapy used for apnea of prematurity (total dose 2233 +/- 1927 mg vs 615 +/- 767 mg, P < ."3.71Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. ( Demianczuk, N; Etches, PC; Robertson, CM; Sreenan, C, 2001)
"Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment."3.70[Treatment of apnea in prematurity]. ( Boutroy, MJ; Hascoët, JM, 1998)
"Doxapram, a respiratory stimulant, is used to treat idiopathic apnea of prematurity."3.70Second-degree atrioventricular heart block after doxapram administration. ( De Villiers, GS; Kalis, NN; Van der Merwe, PL; Walele, A, 1998)
"The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea."3.68Doxapram for the initial treatment of idiopathic apnea of prematurity. ( Bairam, A; Faulon, M; Monin, P; Vert, P, 1992)
"5 mg/kg/h theophylline) were administered in that order and in reverse order to patients with apnea of prematurity."3.68Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity. ( Coutts, RT; Finer, NN; Jamali, F; Malek, F; Peliowski, A, 1991)
"Doxapram was administered orally to six premature babies (3 males, 3 females) with refractory apnea at a mean gestational age of 29 +/- 2."3.68Gastrointestinal absorption of doxapram in neonates. ( Akramoff-Gershan, L; Aranda, JV; Bairam, A; Beharry, K; Laudignon, N; Papageorgiou, A, 1991)
"We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects."3.68Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991)
"5 mg/kg/h) doxapram may help wean from positive airway pressure very low birthweight (less than or equal to 1250 g) infants with apnea unresponsive to aminophylline."3.68Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants. ( Brion, LP; Reinersman, G; Roth, P; Vega-Rich, C, 1991)
"Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2."3.67Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986)
"Eighteen infants with idiopathic apnea of prematurity refractory to therapeutic levels of aminophylline were treated with incremental doses of doxapram beginning at 0."3.67Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, G, 1987)
"Pharmacokinetics of doxapram were determined in 13 infants with idiopathic apnea of prematurity uncontrolled by aminophylline and caffeine."3.67Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ( Beaudry, MA; Bradley, JM; Gramlich, LM; LeGatt, D, 1988)
"Doxapram (2 mg/kg) was tested on 14 occasions in animals which had developed apnoea during chemical restraint."2.68Use of the respiratory stimulant doxapram in southern elephant seals (Mirounga leonina). ( Burton, HR; McLean, S; Nicol, S; Slip, DJ; Woods, R, 1996)
"Doxapram treatment influences aEEG in preterm infants, showing higher percentages of continuous activity as well as more electrographic seizure activity and less sleep-wake cycling."1.40Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants. ( Berger, A; Czaba-Hnizdo, C; Klebermass-Schrehof, K; Olischar, M; Rona, Z; Weninger, M, 2014)
"Doxapram-treated infants were significantly younger and had a lower birth weight."1.39Doxapram and hypokalaemia in very preterm infants. ( Ferdynus, C; Fischer, C; Gouyon, JB; Semama, DS, 2013)
"Doxapram infusion was given to five preterm infants in whom therapeutic concentrations of theophylline had failed to control episodes of apnoea."1.27Idiopathic apnoea of prematurity treated with doxapram and aminophylline. ( Alpan, G; Arad, I; Eyal, F; Patz, D; Sagi, E, 1984)
" Other pharmacokinetic indices, although variable, did not exhibit binomial distribution."1.27Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, GA, 1988)
" At the moment, xanthines are the drugs of choice, since they are both effective and safe, provided dosage is adjusted to each patient."1.26[Drug treatment of apnoea in premature infants (author's transl)]. ( Klethi, J; Mack, G; Messer, J; Willard, D, 1981)
"Doxapram was detected by mass spectrometry for blood and plasma assays, and by flame ionisation for urine assays."1.26Quantitation of doxapram in blood, plasma and urine. ( Moore, RG; Nichol, H; Thomas, J; Vine, J, 1980)

Research

Studies (58)

TimeframeStudies, this research(%)All Research%
pre-199019 (32.76)18.7374
1990's15 (25.86)18.2507
2000's14 (24.14)29.6817
2010's8 (13.79)24.3611
2020's2 (3.45)2.80

Authors

AuthorsStudies
Evans, S1
Avdic, E1
Pessano, S1
Fiander, M1
Soll, R1
Bruschettini, M1
Engbers, AGJ1
Völler, S1
Poets, CF2
Knibbe, CAJ1
Reiss, IKM1
Koch, BCP1
Flint, RB1
Simons, SHP1
de Waal, CG1
Hutten, GJ1
Kraaijenga, JV1
de Jongh, FH1
van Kaam, AH3
Fischer, C1
Ferdynus, C1
Gouyon, JB1
Semama, DS1
Czaba-Hnizdo, C1
Olischar, M1
Rona, Z1
Weninger, M1
Berger, A1
Klebermass-Schrehof, K1
Ogawa, Y1
Irikura, M1
Kobaru, Y1
Tomiyasu, M1
Kochiyama, Y1
Uriu, M1
Ishitsuka, Y1
Kondo, Y1
Yukawa, E1
Kamada, N1
Ohno, H1
Yamazaki, T2
Irie, T1
Ten Hove, CH2
Vliegenthart, RJ2
Te Pas, AB1
Brouwer, E1
Rijken, M1
van Wassenaer-Leemhuis, AG1
Onland, W2
Greze, E1
Benard, M2
Hamon, I2
Casper, C2
Haddad, FE1
Boutroy, MJ4
Hascoët, JM3
Flint, R1
Halbmeijer, N1
Meesters, N1
van Rosmalen, J1
Reiss, I1
van Dijk, M1
Simons, S1
Bhatt-Mehta, V1
Schumacher, RE1
Roll, C1
Horsch, S1
Henderson-Smart, D1
Steer, P3
Marlier, L1
Gaugler, C1
Messer, J2
Glorieux, I1
Dani, C1
Bertini, G1
Pezzati, M1
Pratesi, S1
Filippi, L1
Tronchin, M1
Rubaltelli, FF1
Willard, D1
Mack, G1
Klethi, J1
Sagi, E3
Eyal, F3
Alpan, G3
Patz, D2
Arad, I2
Dear, PR1
Wheeler, D1
Springer, C1
Goder, K1
Nichol, H1
Vine, J1
Thomas, J1
Moore, RG1
Nehlig, A1
Sun, KO1
Woods, R1
McLean, S1
Nicol, S1
Slip, DJ1
Burton, HR1
De Villiers, GS1
Walele, A1
Van der Merwe, PL1
Kalis, NN1
Huon, C1
Rey, E1
Mussat, P1
Parat, S1
Moriette, G1
Darraj, S1
Bohnhorst, B1
Henderson-Smart, DJ4
Steer, PA2
Bhatia, J1
Kajiwara, M1
Itahashi, K1
Fujimura, M1
Sreenan, C1
Etches, PC1
Demianczuk, N1
Robertson, CM1
Bairam, A3
Faulon, M1
Monin, P1
Vert, P2
Brion, LP1
Vega-Rich, C1
Reinersman, G1
Roth, P1
Merchant, RH1
Irani, AJ1
Jamali, F3
Coutts, RT3
Malek, F1
Finer, NN5
Peliowski, A2
Ruggins, NR1
Akramoff-Gershan, L1
Beharry, K1
Laudignon, N1
Papageorgiou, A1
Aranda, JV1
Tay-Uyboco, J1
Kwiatkowski, K1
Cates, DB1
Seifert, B1
Hasan, SU1
Rigatto, H1
Barrington, KJ3
Peters, KL1
Barton, J1
Torok-Both, G1
Clyburn, PA1
Rosen, M1
Torok-Both, GA1
Beaudry, MA1
Bradley, JM1
Gramlich, LM1
LeGatt, D1
Rose, SJ1
Lloyd, DJ1
Duffty, P1
Hayakawa, F1
Hakamada, S1
Kuno, K1
Nakashima, T1
Miyachi, Y1
Cater, G1
Shaffer, S1
Hall, RT1
Glick, B1
Peleg, O1
Dgani, Y1
Zocche, GP1
Musto, P1
Orecchia, C1
Stovner, J1
Plaut, MR1
Gifford, RR1
Jacobsen, PM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants[NCT00389909]Phase 485 participants (Actual)Interventional2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

13 reviews available for doxapram and Apnea

ArticleYear
Doxapram for the prevention and treatment of apnea in preterm infants.
    The Cochrane database of systematic reviews, 2023, 10-25, Volume: 10

    Topics: Aminophylline; Apnea; Caffeine; Doxapram; Humans; Infant, Newborn; Infant, Premature; Lung Diseases

2023
Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
    Neonatology, 2017, Volume: 111, Issue:2

    Topics: Apnea; Caffeine; Doxapram; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infa

2017
Treatment of apnea of prematurity.
    Paediatric drugs, 2003, Volume: 5, Issue:3

    Topics: Aminophylline; Apnea; Caffeine; Clinical Trials as Topic; Doxapram; Humans; Infant, Newborn; Infant,

2003
Doxapram treatment for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2004, Oct-18, Issue:4

    Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea

2004
Effects of respiratory stimulants on cerebral metabolism and blood flow.
    Biology of the neonate, 1994, Volume: 65, Issue:3-4

    Topics: Adult; Animals; Animals, Newborn; Apnea; Brain; Cerebrovascular Circulation; Doxapram; Energy Metabo

1994
Doxapram treatment for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respirator

2000
Doxapram versus methylxanthine for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea

2000
Current options in the management of apnea of prematurity.
    Clinical pediatrics, 2000, Volume: 39, Issue:6

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Prema

2000
Doxapram versus methylxanthine for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2000, Issue:4

    Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea

2000
Risks and benefits of therapies for apnoea in premature infants.
    Drug safety, 2000, Volume: 23, Issue:5

    Topics: Apnea; Doxapram; Feeding Methods; Humans; Infant, Newborn; Infant, Premature; Positive-Pressure Resp

2000
Doxapram treatment for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2001, Issue:4

    Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respirator

2001
Pharmacotherapy of neonatal apnea.
    Indian pediatrics, 1991, Volume: 28, Issue:11

    Topics: Apnea; Caffeine; Citrates; Doxapram; Drug Combinations; Humans; Infant, Newborn; Theophylline

1991
Pathophysiology of apnoea in preterm infants.
    Archives of disease in childhood, 1991, Volume: 66, Issue:1 Spec No

    Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Larynx; Pharynx; Positive-Pre

1991

Trials

10 trials available for doxapram and Apnea

ArticleYear
Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.
    European journal of pediatrics, 2015, Volume: 174, Issue:4

    Topics: Apnea; Asian People; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cytoch

2015
Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial.
    Paediatric drugs, 2016, Volume: 18, Issue:6

    Topics: Apnea; Double-Blind Method; Doxapram; Female; Humans; Infant; Infant, Newborn; Infant, Premature; In

2016
Effect of doxapram on cerebral blood flow velocity in preterm infants.
    Neuropediatrics, 2004, Volume: 35, Issue:2

    Topics: Anterior Cerebral Artery; Apnea; Blood Flow Velocity; Cerebrovascular Circulation; Doxapram; Female;

2004
Olfactory stimulation prevents apnea in premature newborns.
    Pediatrics, 2005, Volume: 115, Issue:1

    Topics: Apnea; Aromatherapy; Bradycardia; Caffeine; Central Nervous System Stimulants; Combined Modality The

2005
Use of the respiratory stimulant doxapram in southern elephant seals (Mirounga leonina).
    The Veterinary record, 1996, May-25, Volume: 138, Issue:21

    Topics: Animals; Apnea; Doxapram; Drug Administration Routes; Female; Intubation; Respiratory System Agents;

1996
Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study.
    Acta paediatrica (Oslo, Norway : 1992), 1998, Volume: 87, Issue:11

    Topics: Apnea; Blood Pressure; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Doxapram; H

1998
Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants.
    Biology of the neonate, 1999, Volume: 76, Issue:4

    Topics: Apnea; Birth Weight; Bradycardia; Caffeine; Doxapram; Drug Resistance; Gestational Age; Humans; Hypo

1999
A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity.
    The Journal of pediatrics, 1990, Volume: 116, Issue:4

    Topics: Apnea; Doxapram; Drug Combinations; Female; Humans; Infant, Newborn; Infant, Premature; Infusions, I

1990
Patient-controlled analgesia with a mixture of pethidine and doxapram hydrochloride. A comparison of the incidence of respiratory dysrhythmias with pethidine alone.
    Anaesthesia, 1988, Volume: 43, Issue:3

    Topics: Adult; Aged; Apnea; Carbon Dioxide; Doxapram; Drug Therapy, Combination; Female; Humans; Male; Meper

1988
Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study.
    Pediatrics, 1985, Volume: 75, Issue:4

    Topics: Aminophylline; Apnea; Double-Blind Method; Doxapram; Drug Resistance; Drug Therapy, Combination; Hum

1985

Other Studies

35 other studies available for doxapram and Apnea

ArticleYear
The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age.
    Neonatology, 2021, Volume: 118, Issue:1

    Topics: Apnea; Caffeine; Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di

2021
Doxapram Treatment and Diaphragmatic Activity in Preterm Infants.
    Neonatology, 2019, Volume: 115, Issue:1

    Topics: Apnea; Birth Weight; Diaphragm; Doxapram; Electromyography; Female; Gestational Age; Humans; Infant,

2019
Doxapram and hypokalaemia in very preterm infants.
    Archives of disease in childhood. Fetal and neonatal edition, 2013, Volume: 98, Issue:5

    Topics: Analysis of Variance; Apnea; Diuretics; Doxapram; Female; Furosemide; Humans; Hypokalemia; Infant, E

2013
Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants.
    Acta paediatrica (Oslo, Norway : 1992), 2014, Volume: 103, Issue:9

    Topics: Apnea; Brain; Doxapram; Electroencephalography; Female; Gestational Age; Humans; Infant, Newborn; In

2014
Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity.
    Neonatology, 2016, Volume: 110, Issue:1

    Topics: Apnea; Bronchopulmonary Dysplasia; Central Nervous System Stimulants; Child Development; Doxapram; D

2016
Retrospective study shows that doxapram therapy avoided the need for endotracheal intubation in most premature neonates.
    Acta paediatrica (Oslo, Norway : 1992), 2017, Volume: 106, Issue:5

    Topics: Apnea; Doxapram; Female; Humans; Infant, Newborn; Infant, Premature; Intubation, Intratracheal; Male

2017
[Determinants of doxapram utilization: a survey of practice in the French Neonatal and Intensive Care Units].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2005, Volume: 12, Issue:2

    Topics: Apnea; Doxapram; France; Health Care Surveys; Humans; Infant, Newborn; Infant, Newborn, Diseases; In

2005
Brain hemodynamic effects of doxapram in preterm infants.
    Biology of the neonate, 2006, Volume: 89, Issue:2

    Topics: Apnea; Birth Weight; Blood Flow Velocity; Brain; Case-Control Studies; Doxapram; Gestational Age; Hu

2006
[Drug treatment of apnoea in premature infants (author's transl)].
    La Nouvelle presse medicale, 1981, Mar-28, Volume: 10, Issue:14

    Topics: Apnea; Chemoreceptor Cells; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Neurotra

1981
Idiopathic apnoea of prematurity treated with doxapram and aminophylline.
    Archives of disease in childhood, 1984, Volume: 59, Issue:3

    Topics: Aminophylline; Apnea; Carbon Dioxide; Doxapram; Drug Therapy, Combination; Female; Humans; Infant, N

1984
Doxapram and neonatal apnoea.
    Archives of disease in childhood, 1984, Volume: 59, Issue:9

    Topics: Apnea; Doxapram; Dyskinesia, Drug-Induced; Humans; Infant, Newborn

1984
Doxapram in the treatment of idiopathic apnea of prematurity unresponsive to aminophylline.
    The Journal of pediatrics, 1984, Volume: 104, Issue:4

    Topics: Aminophylline; Apnea; Doxapram; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature, Dise

1984
Quantitation of doxapram in blood, plasma and urine.
    Journal of chromatography, 1980, May-09, Volume: 182, Issue:2

    Topics: Apnea; Doxapram; Flame Ionization; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Infant,

1980
Doxapram in tubeless anaesthesia for microlaryngeal surgery.
    Anaesthesia and intensive care, 1993, Volume: 21, Issue:2

    Topics: Anesthesia, Intravenous; Apnea; Doxapram; Humans; Intraoperative Complications; Intubation; Intubati

1993
Second-degree atrioventricular heart block after doxapram administration.
    The Journal of pediatrics, 1998, Volume: 133, Issue:1

    Topics: Apnea; Doxapram; Female; Heart Block; Humans; Hyaline Membrane Disease; Infant, Newborn; Infant, Pre

1998
[Treatment of apnea in prematurity].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1998, Volume: 5, Issue:5

    Topics: Apnea; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infa

1998
Low-dose doxapram therapy for idiopathic apnea of prematurity.
    Pediatrics international : official journal of the Japan Pediatric Society, 2001, Volume: 43, Issue:2

    Topics: Apnea; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature; Infant, Prem

2001
Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea.
    The Journal of pediatrics, 2001, Volume: 139, Issue:6

    Topics: Apnea; Case-Control Studies; Cerebral Hemorrhage; Child Development; Developmental Disabilities; Dox

2001
Doxapram for the initial treatment of idiopathic apnea of prematurity.
    Biology of the neonate, 1992, Volume: 61, Issue:4

    Topics: Apnea; Doxapram; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Respiration; To

1992
Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants.
    Journal of perinatology : official journal of the California Perinatal Association, 1991, Volume: 11, Issue:4

    Topics: Aminophylline; Apnea; Benzyl Alcohol; Benzyl Alcohols; Dose-Response Relationship, Drug; Doxapram; D

1991
Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity.
    Developmental pharmacology and therapeutics, 1991, Volume: 16, Issue:2

    Topics: Apnea; Body Weight; Doxapram; Drug Interactions; Female; Gestational Age; Half-Life; Humans; Infant,

1991
Gastrointestinal absorption of doxapram in neonates.
    American journal of perinatology, 1991, Volume: 8, Issue:2

    Topics: Administration, Oral; Apnea; Blood Pressure; Dose-Response Relationship, Drug; Doxapram; Female; Hum

1991
Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity.
    Biology of the neonate, 1991, Volume: 59, Issue:4

    Topics: Apnea; Doxapram; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant, Ne

1991
Low-dose doxapram for apnoea of prematurity.
    Lancet (London, England), 1986, Apr-05, Volume: 1, Issue:8484

    Topics: Apnea; Caffeine; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature, Di

1986
Physiologic effects of doxapram in idiopathic apnea of prematurity.
    The Journal of pediatrics, 1986, Volume: 108, Issue:1

    Topics: Aminophylline; Apnea; Birth Weight; Blood Pressure; Carbon Dioxide; Doxapram; Gestational Age; Human

1986
Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity.
    Pediatrics, 1987, Volume: 80, Issue:1

    Topics: Apnea; Blood Pressure; Carbon Dioxide; Dose-Response Relationship, Drug; Doxapram; Half-Life; Heart

1987
Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data.
    Developmental pharmacology and therapeutics, 1988, Volume: 11, Issue:5

    Topics: Apnea; Doxapram; Drug Administration Schedule; Humans; Infant, Newborn; Infant, Premature, Diseases

1988
Pharmacokinetics of doxapram in idiopathic apnea of prematurity.
    Developmental pharmacology and therapeutics, 1988, Volume: 11, Issue:2

    Topics: Apnea; Doxapram; Female; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases

1988
Doxapram for apnea of prematurity.
    The Journal of pediatrics, 1987, Volume: 111, Issue:1

    Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases

1987
Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentrations.
    The Journal of pediatrics, 1986, Volume: 109, Issue:1

    Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, Parenteral

1986
Doxapram for apnea of prematurity.
    The Journal of pediatrics, 1986, Volume: 109, Issue:3

    Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases

1986
A new analeptic agent: doxapram hydrochloride (Dopram).
    JAMA, 1966, Jun-06, Volume: 196, Issue:10

    Topics: Apnea; Central Nervous System Stimulants; Doxapram; Humans; Postoperative Complications

1966
[Considerations on the use of a new respiratory analeptic, doxapram (3,3-diphenyl-1-ethyl-4-(alpha-morpholinoethyl)-2-pyrrolidone chlorydrate) in the differential diagnosis and treatment of post-narcotic apnea].
    Minerva anestesiologica, 1967, Volume: 33, Issue:11

    Topics: Adult; Aged; Anesthesia; Apnea; Central Nervous System Stimulants; Doxapram; Humans; Middle Aged; Mo

1967
[Doxapram. A respiration stimulator].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1969, Nov-01, Volume: 89, Issue:21

    Topics: Apnea; Central Nervous System Stimulants; Doxapram; Humans; Morpholines; Postoperative Care; Pyrroli

1969
Recovery from central respiratory failure and administration of doxapram to a patient with a brainstem lesion.
    Anesthesiology, 1973, Volume: 38, Issue:6

    Topics: Apnea; Brain Stem; Cerebrovascular Disorders; Coma; Doxapram; Female; Humans; Middle Aged; Quadriple

1973